You just read:

Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

News provided by

Leap Therapeutics, Inc.

Jan 03, 2020, 08:53 ET